Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.

about

Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.

Item

http://www.wikidata.org/entity/Q42334124

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Successful treatment with azac ...... leukemia with concomitant del

@nl

Successful treatment with azac ...... ) and the JAK2 V617F mutation.

@en

type

Item

label

Successful treatment with azac ...... leukemia with concomitant del

@nl

Successful treatment with azac ...... ) and the JAK2 V617F mutation.

@en

prefLabel

Successful treatment with azac ...... leukemia with concomitant del

@nl

Successful treatment with azac ...... ) and the JAK2 V617F mutation.

@en

P1476

Successful treatment with azac ...... ) and the JAK2 V617F mutation.

@en

P2093

Kazuo Ono

http://www.w3.org/2001/XMLSchema#string

Masaharu Nohgawa

http://www.w3.org/2001/XMLSchema#string

Satoko Oka

http://www.w3.org/2001/XMLSchema#string

P2860

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

P304

1411-1413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3032-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28577044

http://www.w3.org/2001/XMLSchema#string

P932

5486789

http://www.w3.org/2001/XMLSchema#string